Virtual Screening, Molecular Docking, and Dynamic Simulations Revealed TGF- β1 Potential Inhibitors to Curtail Cervical Cancer Progression
Appl Biochem Biotechnol. 2023 Jul 1. doi: 10.1007/s12010-023-04608-5. Online ahead of print.ABSTRACTCervical cancer is one of the main causes of cancer death in women globally, and its epidemiology is similar to that of a low-infectious venereal illness. Many sexual partners and early age at first intercourse have been demonstrated to have a significant influence on risk. TGF-β1 is a multifunctional cytokine that is required for cervical carcinoma metastasis, tumor development, progression, and invasion. The TGF-β1 signaling system plays a paradoxical function in cancer formation, suppressing early-stage tumor growth while increasing tumor progression and metastasis. Importantly, TGF-β1 and TGF-β receptor 1 (TGF-βR1), two components of the TGF-β signaling system, are substantially expressed in a range of cancers, including breast cancer, colon cancer, gastric cancer, and hepatocellular carcinoma. The current study aims to investigate possible inhibitors targeting TGF-β1 using molecular docking and dynamic simulations. To target TGF-β1, we used anti-cancer drugs and small molecules. MVD was utilized for virtual screening, and the highest scoring compound was then subjected to MD simulations using Schrodinger software package v2017-1 (Maestro v11.1) to identify the most favorable lead interactions against TGF-β1. The Nilotinib compound has shown the least XP Gscore of -2.581 kcal/mol, 30ns MD simulations revealing that the Nilotinib- TGF-β1 complex possesses the lowes...
Source: Applied Biochemistry and Biotechnology - Category: Biochemistry Authors: Pavan Kumar Poleboyina Umakanth Naik Akbar Pasha Doneti Ravinder Shivaji Bhanothu Sneha Malleswari Poleboyina Umamaheshwari Amineni Smita C Pawar Source Type: research
More News: Biochemistry | Biotechnology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colon Cancer | Colorectal Cancer | Epidemiology | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Nilotinib | Study | Tasigna | Women